Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized placebo-controlled IFX-1 study in moderate to severe hidradenitis suppurativa
NL-OMON46646Phase 2Active, not recruiting
- Sponsor
- InflaRx
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing IFX-1 with Placebo (2 arms). Primary endpoint: HiSCR response at Week 16. Started Aug 2018; status: active, not recruiting.
02
Drugs
vilobelimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NL-OMON46646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46646.